(Q41240864)

English

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

E Aklillu

5

0 references

author name string

B A Maganda

1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

O M S Minzi

2

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

E Ngaimisi

3

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

A A R Kamuhabwa

4

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

publication date

12 May 2015

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

The Pharmacogenomics Journal

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

88-95

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Increased severity and mortality in adults co-infected with malaria and HIV in Maputo, Mozambique: a prospective cross-sectional study

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Effect of malaria on HIV/AIDS transmission and progression

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Evidence for an increased risk of transmission of simian immunodeficiency virus and malaria in a rhesus macaque coinfection model

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Dynamics of Plasmodium falciparum selection after artemether-lumefantrine treatment in Africa

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Clinical pharmacology of artemisinin-based combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Colonisation and mass rearing: learning from others

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Induction of multiple drug transporters by efavirenz

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

A fast and reliable reversed phase high performance liquid chromatography method for simultaneous determination of selected anti-retroviral and lumefantrine in human plasma

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Genetic variations in ABCB1 and CYP3A5 as well as sex influence quinine disposition among Ugandans

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2015.37

21 January 2018

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

1 reference

https://pubmed.ncbi.nlm.nih.gov/25963334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25963334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Understanding the pharmacokinetics of Coartem

1 reference

https://pubmed.ncbi.nlm.nih.gov/25963334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/25963334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations

1 reference

https://pubmed.ncbi.nlm.nih.gov/25963334

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/TPJ.2015.37

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41240864&oldid=2204406001"